AAW Pharmaceuticals partners with global pharmaceutical leader ‘Takeda’
With the increasing demand of high quality pharmaceutical products for Kuwait’s growing population, Ali Abdulwahab Al Mutawa Commercial Co. (AAW) announced a partnership agreement with Japan-based pharmaceutical company Takeda Pharmaceutical Company Limited (Takeda), the largest pharmaceutical company in Asia, to distribute a new and wide range of high-quality pharmaceutical products in Kuwait’s healthcare sector.
Currently present in over 70 countries, Takeda is one of the world’s largest 15 pharmaceutical companies in the world with over 30,000 employees spread across the globe and over 21 research and development centers.
AAW General Manager of Pharmaceuticals, Dr. Sherif Younan, said, “Our strategic partnership with Takeda will enable us to offer globally-leading, cutting-edge pharmaceutical products from a global quality provider, and to empower healthcare professionals in their mission to help their patients. We look forward to growing our relationship with Takeda for the benefit of Kuwait’s healthcare providers and their patients.”
Takeda GCC Managing Director, Mr. Ahdy Alsayes, said, “This strategic partnership agreement reflects our deep commitment towards Kuwait. We look forward to building on our established portfolio over the coming few years through this partnership with one of the leading companies in Kuwait that has a proven track record in this sector, supported by our plans of launching a number of innovative products in critical treatment areas such as hypertension, cardiovascular metabolic, gastroenterology and respiratory markets.”
AAW is one of the largest trading and commercial companies in Kuwait and operates in multiple consumer, pharmaceutical, and retail sectors. The company’s pharmaceutical division is one of the company’s oldest divisions with an operation spanning over 50 years and a portfolio of global products from global pharmaceutical companies, such as Roche, Biotronik, Bioderma, Nuxe, and now, Takeda.
For more inquiries, please contact:
Bensirri Public Relations